Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | The MURANO study: key findings

John Seymour • 23 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Bendamustine Rituximab Venetoclax
MURANO

John Seymour, MBBS, PhD, Peter MacCallum Cancer Center, Melbourne, Australia discusses the biological subsets, safety analysis and serial measurable residual disease (MRD) within the MURANO study (NCT02005471). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from John Seymour

PROTACs as an emerging new drug class to treat hematologic malignancies 1:34
PROTACs as an emerging new drug class to treat hematologic malignancies
John Seymour • 6 Sep 2024
Treating CLL in the R/R setting: switching drug classes and investigational therapies 1:49
Treating CLL in the R/R setting: switching drug classes and investigational therapies
John Seymour • 6 Sep 2024
The evolution of BCL2 inhibition in CLL 2:01
The evolution of BCL2 inhibition in CLL
John Seymour • 6 Sep 2024
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies 3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals